Rainbow Seed Fund

Rainbow Seed Fund

The Rainbow Seed Fund is a £24m, early-stage venture capital fund dedicated to kick-starting promising technology companies developed at some of the UK’s largest publicly-funded research facilities.  These companies are linked to the rapidly expanding science and technology campuses and the field of synthetic biology.

Created in 2002, the Rainbow Seed Fund is backed by ten UK publicly-funded research organisations and the Department of Business, Innovation and Skills (BIS). The Fund holds investments in some of the UK’s most innovative companies in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.

 

Rainbow Seed Fund Investments

We’re prepared to invest early and help build a commercial proposition around a technology to attract additional investment needed to get to market.

The Rainbow Seed Fund invests in:

1. Projects and companies arising from the world-class research carried out in our Partner laboratories across the UK, including those at Rutherford Appleton Laboratory (STFC), Porton Down (Dstl) and Babraham Institute (BBSRC).  View full list of partners.

2. Companies based at our partners’ national science and innovation campuses in Oxford, Cambridge, Warrington and Norwich. Read more about partner campuses.


Babraham-Research-Campus-smallHarwell-Oxford  Sci Tech Daresbury 2Norwich Research

3. Companies working in the field of synthetic biology:  Synthetic biology is an exciting new discipline based on the design and engineering of biologically-based parts, novel devices and systems and the redesign of existing, natural biological systems.

 

Rainbow Seed Fund Milestones

Over the past decade, the Rainbow Seed Fund has:

  • Supported 30+ technology start-up companies in sectors such as health, environmental services, international development, and security and defense.
  • Leveraged more than £150 million of private investment from just £7 million of its own investment (a ratio of over £20 for every £1 from Rainbow).
  • Bolstered the UK’s exports and employment — 75%-100% of Rainbow Seed Fund company sales are overseas and our companies have created 170+ high-value, technology jobs.
  • In recognition of these achievements, in November 2013 the Rainbow Seed Fund received an additional £10M investment to support the commercialisation of synthetic biology technologies. This funding was in response to the Synthetic Biology Roadmap, which sets out plans to harness opportunities in the field of synthetic biology. Synthetic biology is one of the eight great technologies highlighted by the UK government as an area of wide-ranging significance and potential economic importance, and in which the UK’s research base is particularly strong.

 

Additional Background

 

Rainbow Seed Fund Partners

Partners

The Rainbow Seed Fund is independently managed by Dr. Andrew Muir and Mark White at Midven.

Fund Facts

Fund Amount 24m

2 Profitable Exits

30 Companies

Fund Managers

Associated Investments

Watch

Relevant News

Rainbow Seed Fund & University of Birmingham Back Promising Technology Spinout Linear Diagnostics

Spinout developing novel hand-held reader to help in the fight against antibiotic resistance 24 May…

read more

Nemesis Bioscience Closes Funding Round And Begins Preclinical Programmes

Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed…

read more

Cytox Plans US Clinical Launch for Early-Stage Alzheimer's Test While Courting Pharma Partners

British molecular diagnostics company Cytox plans to make a molecular test for the early-stage diagnosis…

read more

Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m

Collaboration to generate tumor targeting drug conjugates and immuno-oncology therapeutics Crescendo Biologics Limited (Crescendo), the…

read more

Rainbow Seed Fund Backs New STFC Spin Out MIRICO

Spin out from UK publicly-funded research develops novel laser spectroscopy for environmental, medical diagnosis and…

read more

Synthace Partners With Microsoft To Bring Antha To Azure

Synthace Ltd., a London based technology company developing Antha, a high level language and operating…

read more

Gene Therapy Company Quethera Obtains Grant From Wellcome Trust Pathfinder Award Scheme

Quethera Ltd, a privately funded gene therapy company based at the Babraham Research Campus in…

read more

Crescendo Biologics Appoints Dr Barbara Fleck as Head of Intellectual Property

Cambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer…

read more

Contego Announces Selection Into Accenture's Innovation Lab

January 7th, 2016 -- Contego announces today that it is part of the Accenture FinTech…

read more

Crescendo Biologics Appoints Dr Kevin Johnson as Chairman

Antibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus Cambridge, UK: 17…

read more

Crescendo Biologics Launches New Strategy In Oncology Drug Discovery & Development

Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics, has announced the…

read more

States Can Provide Seed Capital To Spur Growth

Read the thoughts of Chris Martin Non Executive Directors on the Rainbow Seed Advisory board…

read more

Dow AgroSciences, Synthace Research Collaboration to Accelerate Product Development Using High Tech Tools

Synthace and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE:DOW), today…

read more

Desktop Genetics Ltd Raises £1.37 Million GBP ($2.15M USD) Funding

  Desktop Genetics Ltd (“DTG” or “the Com pany”), a UK bioinformatics company aiming to…

read more

Quethera Announces Seed Financing To Develop Gene Therapy Aimed At Preventing Blindness In Glaucoma Patients

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has…

read more

Oxford Space Systems Secures £1.2m Investment

Oxford Space Systems (OSS) has successfully secured £1.2m in its second round fund raise from…

read more

Tokamak Energy Named as a Technology Pioneer by World Economic Forum

World Economic Forum today announced its selection of the world’s 49 most promising Technology Pioneers…

read more

The New Shape of Fusion

ITER, the international fusion reactor being built in France, will stand 10 stories tall, weigh…

read more

BioSyntha and ZuvaChem Announce a Merger and Financing to Form ZuvaSyntha Ltd

Combining excellence in industrial biotechnology May 18th, 2015 – Welwyn Garden City, UK and Baltimore,…

read more

Rainbow Seed Fund Expands Team To Drive Synthetic Biology Investments

Fund Adds Life Science Commercialisation Expert Oliver Sexton to Investment Team and Renewables Entrepreneur Sean…

read more

Visual Clarity For All Spectral Edge Announces Investment by The Rainbow Seed Fund

18 July 2014 - Spectral Edge announces today the completion of a £300K financing round…

read more

KEIT: Going Where No Human Or Machine Has Been Before

Parts of our planet are so hostile they are unreachable. But if we are to…

read more

New Funds To Drive Development Of Best-in-Class Fully Human VH antibody Fragment Therapeutics

VH domains are the smallest, most robust antibody fragments and as such have advantages for…

read more

CellCentric Gains £4.3m To Take Prostate Cancer Programme Through To Clinical Candidates

New investment coupled with a major award from the UK’s innovation agency, the Technology Strategy…

read more

Mars To Volcanoes, Ash Clouds and Chimneystacks-UK Spin-Out Brings Space Technology to Earth

KEIT Ltd is a brand new, forward thinking spin out company from the Science and…

read more

£100,000 Investment For Microbiology Company

A Company which offers bespoke microbiological testing has secured £100,000 investment. Perfectus Biomed, based at…

read more

Parker Aerospace and Oxsensis To Develop Highly Accurate Stable Fiber Optic Pressure Sensor

Suitable for low temperatures and high vibrations, immune to EMI Reduces system weight and complexity…

read more

Aitua Enters Into Option Agreement With Nicox To Acquire Altacor

NicOx enters into option agreement to acquire Altacor as a first step towards building an…

read more

Cobalt Light Systems Receives European Approval For It's Bottle Scanner

Tue, 17/01/2012 - 12:26 Cobalt Light Systems has received European approval for its revolutionary INSIGHT100…

read more

New Antibiotic Compound Enters Phase 1 Clinical Trial

Novacta Biosystems has commenced dosing of the first healthy volunteers in a phase 1 clinical…

read more

P2i Demonstrates Magical Protective Liquid Repellent Nano-Coating For Smartphones At IFA 2011

Just one drop of liquid can destroy your phone or tablet! Acting like a barrier,…

read more

Crescendo Biologics Appoints Matthew Roe as Chief Business Officer

Cambridge, UK. 22 June 2011 – Crescendo Biologics Limited (Crescendo) today announces the appointment of…

read more

Mike Romanos Appointed CEO Of Crescendo Biologics

UK. 12 October 2009 - Mike Romanos has been appointed Chief Scientific Officer of Crescendo…

read more

Case Studies

Case Study - ZuvaSyntha Ltd

  Summary: ZuvaSyntha is developing proprietary renewable manufacturing routes to industrial chemicals from low cost…

read more